8.28  0.1 (1.22%)		01-02 16:00
Open: 8.275 High: 8.3811 Volume: 716,528		Pre. Close: 8.18 Low: 8.14 Market Cap: 413(M)

Short term
Mid term
Targets	6-month :	8.51	1-year :	9.98
Resists	First :	7.28	Second :	8.54
Pivot price	7.03
Supports	First :	5.24	Second :	4.36
MAs	MA(5) :	6.98	MA(20) :	6.83
	MA(100) :	6.74	MA(250) :	6.97
MACD	MACD :	-0.1	Signal :	0
%K %D	K(14,3) :	36.5	D(3) :	65.4
RSI	RSI(14): 36
52-week	High :	9.82	Low :	4.8

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ CYBN ] has closed below the lower bollinger band by 2.9%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ CYBN ] is to continue within current trading range. It is unclear right now based on current values. 96.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	6.8 - 6.84	6.84 - 6.87
Low:	5.21 - 5.23	5.23 - 5.26
Close:	5.59 - 5.64	5.64 - 5.68

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

Thu, 05 Mar 2026
Cybin (CYBN) unit Helus shows promising Phase 2 anxiety results for HLP004 - Stock Titan

Tue, 03 Mar 2026
HELP Stock Price and Chart — NEO:HELP - TradingView

Fri, 19 Dec 2025
Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq - Business Wire

Wed, 03 Dec 2025
Guggenheim raises Cybin stock price target to $48 on clinical progress - Investing.com

Thu, 20 Nov 2025
Cybin Inc (CYBN) Q2 2026 Earnings Call Highlights: Strategic Advancements Amid Financial Challenges - Yahoo Finance

Fri, 14 Nov 2025
HC Wainwright & Co. Maintains Cybin (CYBN) Buy Recommendation - Nasdaq

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.